Immunology Today—June 10, 2026

This week’s Immunology update highlights regulatory progress, clinical data on autoimmune and kidney diseases, and new therapy developments.

In Today’s Newsletter

Dive deeper

🧬 Ultomiris IgA nephropathy Phase 3 interim data [1] [UK • 06 Jun 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/ultomiris-demonstrated-43-4-reduction-in-proteinuri-vs-placebo-in-adults-with-immunoglobulin-i-can-phase-iii-trial.html
Context: AstraZeneca reported prespecified interim Phase 3 I CAN data in adults with IgA nephropathy at risk of progression.
Key point: Ultomiris (ravulizumab) showed a 43.4% placebo-adjusted reduction in 24-hour UPCR at week 34.
Implication: May influence prescriber choice and payer reviews pending full data.

🦴 Cosentyx polymyalgia rheumatica Phase 3 data [2] [EU • 03 Jun 2026]

https://www.novartis.com/news/media-releases/novartis-cosentyx-pmr-data-new-england-journal-medicine-showed-sustained-remission-vs-placebo-twice-many-patients
Context: Novartis presented Phase 3 REPLENISH data in polymyalgia rheumatica, with publication in NEJM.
Key point: Cosentyx (secukinumab) achieved higher sustained remission versus placebo through week 52 and reduced steroid use.
Implication: May influence prescriber choice and payer reviews pending full data.

🫘 VOYXACT IgA nephropathy eGFR data [3] [UK • 05 Jun 2026]

https://www.otsuka.co.jp/en/company/newsreleases/2026/20260605_2.html
Context: Otsuka reported prespecified interim Phase 3 VISIONARY data in adults with primary IgA nephropathy.
Key point: VOYXACT (sibeprenlimab-szsi) preserved kidney function at 12 months, with mean eGFR change of +0.7 versus -4.8 mL/min/1.73 m² for placebo.
Implication: May influence prescriber choice and payer reviews pending full data.

🛡️ Nipocalimab systemic lupus erythematosus Phase 2 data [4] [UK • 03 Jun 2026]

https://www.jnj.com/media-center/press-releases/johnson-johnson-late-breaking-results-show-nipocalimab-significantly-reduced-systemic-lupus-erythematosus-sle-disease-activity-in-a-phase-2-study
Context: Johnson & Johnson reported Phase 2 JASMINE data in adults with moderate-to-severe systemic lupus erythematosus.
Key point: Nipocalimab met the week 24 primary endpoint on SRI-4 and showed sustained disease-activity reduction through week 52.
Implication: May influence prescriber choice and payer reviews pending full data.

💧 Nipocalimab Sjögren’s disease biomarker data [5] [UK • 03 Jun 2026]

https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-further-reinforcing-the-role-of-nipocalimab-in-lowering-the-autoantibodies-driving-sjogrens-disease
Context: Johnson & Johnson reported exploratory biomarker analyses from Phase 2 DAHLIAS in moderate-to-severe Sjögren’s disease.
Key point: Participants with elevated autoantibodies and IgG had greater clinical response rates with nipocalimab.
Implication: May influence prescriber choice and payer reviews pending full data.

🧴 Genital psoriasis age-specific consensus guidance [6] [US • 03 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/03/3305996/0/en/new-expert-consensus-provides-age-specific-guidance-for-improving-care-for-individuals-with-genital-psoriasis-published-in-the-american-journal-of-clinical-dermatology.html
Context: Arcutis announced a Genital Psoriasis Wellness Consortium manuscript in the American Journal of Clinical Dermatology.
Key point: The consensus gives age-specific guidance for recognition, diagnosis, and management across pediatric, adult, and older populations.
Implication: May expand screening, initiation, and follow-up at scale.

💇 CG2001 androgenetic alopecia Phase 2 topline data [7] [South Korea • 08 Jun 2026]

https://www.manilatimes.net/2026/06/08/tmt-newswire/pr-newswire/dayspring-pharma-announces-positive-topline-results-from-phase-ii-clinical-trial-of-cg2001-for-the-treatment-of-androgenetic-alopecia-aga/2360333
Context: Dayspring Pharma reported Phase 2 data for CG2001, a topical minoxidil and finasteride fixed-dose combination.
Key point: CG2001 5% minoxidil and 0.075% finasteride twice daily met the week 24 primary endpoint for Target Area Hair Count versus placebo.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

IgA nephropathy competition is intensifying, with AstraZeneca and Otsuka presenting differentiated renal endpoints in the same week. [1][3]
Nipocalimab is expanding its autoimmune evidence base across SLE and Sjögren’s disease, both autoantibody-linked conditions. [4][5]
Cosentyx PMR data add a steroid-sparing angle in a disease with limited advanced treatment options. [2]
Dermatology updates span both care-process guidance and drug-development readouts, from genital psoriasis consensus to alopecia Phase 2 data. [6][7]

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Immunology archive on our research hub page.

FAQ

What did Ultomiris show in IgA nephropathy?

Ultomiris (ravulizumab) reduced proteinuria versus placebo in AstraZeneca’s Phase 3 I CAN interim analysis. The primary eGFR endpoint is planned at week 106. [1]

How did Cosentyx perform in polymyalgia rheumatica?

Cosentyx (secukinumab) achieved higher sustained remission versus placebo through week 52 in Phase 3 REPLENISH. Novartis also reported reduced steroid use. [2]

What is notable about VOYXACT in IgA nephropathy?

VOYXACT (sibeprenlimab-szsi) preserved kidney function versus placebo at 12 months in interim Phase 3 VISIONARY data. Otsuka linked the result to selective APRIL inhibition. [3]

What did J&J report for nipocalimab in SLE?

Nipocalimab met the week 24 primary endpoint in Phase 2 JASMINE and showed sustained disease-activity reduction through week 52. Phase 3 GARDENIA is recruiting. [4]

What did nipocalimab show in Sjögren’s disease?

Exploratory Phase 2 DAHLIAS analyses showed greater response rates in participants with elevated autoantibodies and IgG. The Phase 3 DAFFODIL study is ongoing. [5]

What is CG2001?

CG2001 is Dayspring Pharma’s topical fixed-dose minoxidil and finasteride combination for male androgenetic alopecia. It met the Phase 2 week 24 primary endpoint for Target Area Hair Count versus placebo. [7]

Entities / Keywords

Ultomiris, ravulizumab, AstraZeneca, Alexion, IgA nephropathy, IgAN, I CAN, UPCR, proteinuria, terminal complement inhibition
Cosentyx, secukinumab, Novartis, polymyalgia rheumatica, PMR, REPLENISH, IL-17A, glucocorticoid sparing
VOYXACT, sibeprenlimab-szsi, Otsuka, IgA nephropathy, VISIONARY, eGFR, APRIL inhibition, Gd-IgA1
Nipocalimab, Johnson & Johnson, J&J, FcRn blocker, systemic lupus erythematosus, SLE, JASMINE, SRI-4, LLDAS
Nipocalimab, Sjögren’s disease, SjD, DAHLIAS, DAFFODIL, IgG autoantibodies, ClinESSDAI
Arcutis Biotherapeutics, Genital Psoriasis Wellness Consortium, genital psoriasis, plaque psoriasis, Delphi consensus
Dayspring Pharma, CG2001, androgenetic alopecia, AGA, minoxidil, finasteride, Target Area Hair Count, TAHC